Resistance to HER2 inhibitors: Is addition better than substitution? Rationale for the hypothetical concept of drug sedimentation

Critical Reviews in Oncology/Hematology

Volumn 78, Issue 3, 2011, Pages 195-205

  Campone, Mario ^a,b   Juin, Philippe ^b,c   André, Fabrice ^d   Bachelot, Thomas ^e  

^a CENTRE RENÉ GAUDUCHEAU   (France)

^b Groupe Cytokines et Récepteurs   (France)

^c UNIVERSITÉ DE NANTES   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e CENTRE LÉON BÉRARD   (France)

Author keywords

Lapatinib; Predictive factors; Resistance; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 90; LAPATINIB; PACLITAXEL; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SCATTER FACTOR RECEPTOR; SOMATOMEDIN RECEPTOR; TRASTUZUMAB;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER COMBINATION CHEMOTHERAPY; COMPLEX FORMATION; DIMERIZATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG RESPONSE; DRUG TREATMENT FAILURE; HUMAN; LOADING DRUG DOSE; MONOTHERAPY; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 79955658799     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2010.04.012     Document Type: Review

References (64)

1. Moasser M.M. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 2007, 26:6469-6487.
2. Moasser M.M. Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene 2007, 26:6577-6592.
3. Vogel C.L., Cobleigh M.A., Tripathy D., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002, 20:719-726.
4. Gomez H.L., Doval D.C., Chavez M.A., et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 2008, 26:2999-3005.
5. King C.R., Kraus M.H., Aaronson S.A. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 1985, 229:974-976.
6. Baasner S., von Melchner H., Klenner T., Hilgard P., Beckers T. Reversible tumorigenesis in mice by conditional expression of the HER2/c-erbB2 receptor tyrosine kinase. Oncogene 1996, 13:901-911.
7. Schiffer I.B., Gebhard S., Heimerdinger C.K., et al. Switching off HER-2/neu in a tetracycline-controlled mouse tumor model leads to apoptosis and tumor-size-dependent remission. Cancer Res 2003, 63:7221-7231.
8. Xie W., Chow L.T., Paterson A.J., Chin E., Kudlow J.E. Conditional expression of the ErbB2 oncogene elicits reversible hyperplasia in stratified epithelia and up-regulation of TGFalpha expression in transgenic mice. Oncogene 1999, 18:3593-3607.
9. Slamon D.J., Godolphin W., Jones L.A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712.
10. Tronick S.R., Aaronson S.A. Growth factor and signal transduction. Molecular basis of cancer 1995, 117-140. Saunders, Philadelphia. J. Mendelsohn, P.H. Howley, M.A. Israel, L.A. Liotta (Eds.).
11. Slichenmyer W.J., Fry D.W. Anticancer therapy targeting the erbB family of receptor tyrosine kinases. Semin Oncol 2001, 28(Suppl. 16):67-79.
12. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2:127-137.
13. Cho H.S., Mason K., Ramyar K.X., et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003, 421:756-760.
14. Hsieh A.C., Moasser M.M. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer 2007, 97:453-457.
15. Baselga J., Norton L., Albanell J., Kim Y.M., Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998, 58:2825-2831.
16. Merlin J.L., Barberi-Heyob M., Bachmann N. In vitro comparative evaluation of trastuzumab (Herceptin) combined with paclitaxel (Taxol) or docetaxel (Taxotere) in HER2-expressing human breast cancer cell lines. Ann Oncol 2002, 13:1743-1748.
17. Pegram M.D., Konecny G.E., O'Callaghan C., Beryt M., Pietras R., Slamon DJ Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004, 96:739-749.
18. Cuello M., Ettenberg S.A., Clark A.S., et al. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res 2001, 61:4892-4900.
19. Diermeier S., Horváth G., Knuechel-Clarke R., Hofstaedter F., Szöllosi J., Brockhoff G. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Exp Cell Res 2005, 304:604-619.
20. Valabrega G., Montemurro F., Sarotto I., et al. TGFalpha expression impairs trastuzumab-induced HER2 downregulation. Oncogene 2005, 24:3002-3010.
21. Molina M.A., Codony-Servat J., Albanell J., Rojo F., Arribas J., Baselga J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 2001, 61:4744-4749.
22. Lane H.A., Beuvink I., Motoyama A.B., Daly J.M., Neve R.M., Hynes N.E. ErbB2 potentiates breast tumor proliferation through modulation of p27 (Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol Cell Biol 2000, 20:3210-3223.
23. Marches R., Uhr J.W. Enhancement of the p27Kip1-mediated antiproliferative effect of trastuzumab (Herceptin) on HER2-overexpressing tumor cells. Int J Cancer 2004, 112:492-501.
24. Le X.F., Pruefer F., Bast R.C. HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways. Cell Cycle 2005, 4:87-95.
25. Asanuma H., Torigoe T., Kamiguchi K., et al. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells. Cancer Res 2005, 65:11018-11025.
26. Henson E.S., Hu X., Gibson S.B. Herceptin sensitizes ErbB2-overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 expression. Clin Cancer Res 2006, 12:845-853.
27. Carter P., Presta L., Gorman C.M., et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992, 89:4285-4289.
28. Clynes R.A., Towers T.L., Presta L.G., Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000, 6:443-446.
29. Gennari R., Menard S., Fagnoni F., et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004, 10:5650-5655.
30. Medina P.J., Goodin S. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther 2008, 30:1426-1447.
31. Cobleigh M.A., Vogel C.L., Tripathy D., et al. In women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999, 17:2639-2648.
32. Burstein H.J., Storniolo A.M., Franco S., et al. A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol 2008, 19:1068-1074.
33. Johnston S., Trudeau M., Kaufman B., et al. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol 2008, 26:1066-1072.
34. Blackwell K.L., Burstein H., Pegram M., et al. Determining relevant biomarkers from tissue and serum that may predict response to single agent lapatinib in trastuzumab refractory metastatic breast cancer. J Clin Oncol 2005, 23(Suppl.):3004. [abstract].
35. Nagy P., Friedländer E., Tanner M., et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 2005, 65:473-482.
36. Pályi-Krekk Z., Barok M., Isola J., Tammi M., Szöllosi J., Nagy P. Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer. Eur J Cancer 2007, 43:2423-2433.
37. Di Fiore P.P., Pierce J.H., Kraus M.H., Segatto O., King C.R., Aaronson S.A. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 1987, 237:178-182.
38. Segatto O., King C.R., Pierce J.H., Di Fiore P.P., Aaronson S.A. Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene. Mol Cell Biol 1988, 8:5570-5574.
39. Xia W., Liu L.H., Ho P., Spector N.L. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene 2004, 23:646-653.
40. Anido J., Scaltriti M., Bech Serra J.J., et al. Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. EMBO J 2006, 25:3234-3244.
41. Agus D.B., Akita R.W., Fox W.D., et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002, 2:127-137.
42. Ritter C.A., Perez-Torres M., Rinehart C., et al. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 2007, 13:4909-4919.
43. Lu Y., Zi X., Zhao Y., Mascarenhas D., Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001, 93:1852-1857.
44. Nahta R., Yuan L.X., Zhang B., Kobayashi R., Esteva F.J. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005, 65:11118-11128.
45. Shattuck D.L., Miller J.K., Carraway K.L., Sweeney C. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res 2008, 68:1471-1477.
46. Nagata Y., Lan K.H., Zhou X., et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6:117-127.
47. Garrido C., Gurbuxani S., Ravagnan L., Kroemer G. Heat shock proteins: endogenous modulators of apoptotic cell death. Biochem Biophys Res Commun 2001, 286:433-442.
48. Zsebik B., Citri A., Isola J., Yarden Y., Szöllosi J., Vereb G. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1. Immunol Lett 2006, 104:146-155.
49. Kang S.H., Kang K.W., Kim K.H., et al. Upregulated HSP27 in human breast cancer cells reduces Herceptin susceptibility by increasing Her2 protein stability. BMC Cancer 2008, 8:286.
50. Eichhorn P.J., Gili M., Scaltriti M., et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 2008, 68:9221-9230.
51. Xiang B., Chatti K., Qiu H., et al. Brk is coamplified with ErbB2 to promote proliferation in breast cancer. Proc Natl Acad Sci USA 2008, 105:12463-12468.
52. Sergina N.V., Rausch M., Wang D., et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007, 445:437-441.
53. Xia W., Bacus S., Hegde P., et al. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci USA 2006, 103:7795-7800.
54. Weinstein I.B., Begemann M., Zhou P., et al. Disorders in cell circuitry associated with multistage carcinogenesis: exploitable targets for cancer prevention and therapy. Clin Cancer Res 1997, 3:2696-2702.
55. Perou C.M., Sørlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
56. Sharma S.V., Gajowniczek P., Way I.P., et al. A common signaling cascade may underlie "addiction" to the Src BCR-ABL, and EGF receptor oncogenes. Cancer Cell 2006, 10:425-435.
57. Evan G.I. Can't kick that oncogene habit. Cancer Cell 2006, 10:345-347.
58. Demicheli R., Retsky M.W., Swartzendruber D.E., Bonadonna G. Proposal for a new model of breast cancer metastatic development. Ann Oncol 1997, 8:1075-1080.
59. Braun S., Vogl F.D., Naume B., et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005, 353:793-802.
60. O'Shaughnessy J., Blackwell K.L., Burstein H., et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. J Clin Oncol 2008, 26(Suppl.):1015. [abstract].
61. Baselga J., Cameron D., Miles D., et al. Objective response rate in a phase II multicenter trial of pertuzumab (P), a HER2 dimerization inhibiting monoclonal antibody, in combination with trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC) which has progressed during treatment with T. J Clin Oncol 2007, 25(Suppl.):1004. [abstract].
62. Modi S., Stopeck A., Kinden H., et al. Tanespimycin (an Hsp90 inhibitor) and trastuzumab is an active combination in patients (pts) with Her2-positive trastuzumab-refractory metastatic breast cancer (MBC): phase 2 trial. San Antonio breast cancer symposium 2007, 6066. [abstract].
63. André F., Campone M., Hurvitz S.A., et al. Multicenter phase I clinical trial of daily and weekly RAD001 in combination with weekly paclitaxel and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab. J Clin Oncol 2008, 26(Suppl.):1003. [abstract].
64. Pegram M., Chan D., Dichmann R.A., et al. Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplified breast cancer. San Antonio breast cancer symposium 2007, 301. [abstract].